Document detail
ID
oai:pubmedcentral.nih.gov:8596...
Topic
Regular Issue ArticlesAuthor
Videnovic, Aleksandar Amara, Amy W. Comella, Cynthia Schweitzer, Paula K. Emsellem, Helene Liu, Kris Sterkel, Amanda L. Gottwald, Mildred D. Steinerman, Joshua R. Jochelson, Philip Zomorodi, Katie Hauser, Robert A.Langue
enEditor
John Wiley & Sons, Inc.
Category
Wiley-Blackwell Online Open
Year
2021
listing date
12/1/2023
Keywords
sleepiness parkinson 1% pd eds solriamfetol placeboAbstract
BACKGROUND: Solriamfetol is approved (US and EU) for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea.
OBJECTIVES: Evaluate solriamfetol safety/efficacy for EDS in Parkinson's disease (PD).
METHODS: Phase 2, double‐blind, 4‐week, crossover trial: adults with PD and EDS were randomized to sequence A (placebo, solriamfetol 75, 150, 300 mg/d), B (solriamfetol 75, 150, 300 mg/d, placebo), or C (placebo).
Outcomes (safety/tolerability [primary]; Epworth Sleepiness Scale [ESS]; Maintenance of Wakefulness Test [MWT]) were assessed weekly.
P values are nominal.
RESULTS: Common adverse events (n = 66): nausea (10.7%), dizziness (7.1%), dry mouth (7.1%), headache (7.1%), anxiety (5.4%), constipation (5.4%), dyspepsia (5.4%).
ESS decreased both placebo (−4.78) and solriamfetol (−4.82 to −5.72; P > 0.05).
MWT improved dose‐dependently with solriamfetol, increasing by 5.05 minutes with 300 mg relative to placebo (P = 0.0098).
CONCLUSIONS: Safety/tolerability was consistent with solriamfetol's known profile.
There were no significant improvements on ESS; MWT results suggest possible benefit with solriamfetol in PD.
© 2021 The Authors.
Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Videnovic, Aleksandar,Amara, Amy W.,Comella, Cynthia,Schweitzer, Paula K.,Emsellem, Helene,Liu, Kris,Sterkel, Amanda L.,Gottwald, Mildred D.,Steinerman, Joshua R.,Jochelson, Philip,Zomorodi, Katie,Hauser, Robert A., 2021, Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial, John Wiley & Sons, Inc.
